Scarica l'app Stockscreener
3.3819
3.37%
-0.1181
Dopo l'orario di chiusura:
3.54
0.1581
+4.67%
Precedente Chiudi:
$3.50
Aprire:
$3.5681
Volume 24 ore:
31,870
Relative Volume:
2.23
Capitalizzazione di mercato:
$372.13M
Reddito:
$16.82M
Utile/perdita netta:
$-112.19M
Rapporto P/E:
-1.5245
EPS:
-2.2183
Flusso di cassa netto:
$-91.84M
1 W Prestazione:
-13.06%
1M Prestazione:
+9.09%
6M Prestazione:
+22.98%
1 anno Prestazione:
+5.68%
Intervallo 1D:
$3.30
$3.7307
Intervallo di 1 settimana:
$3.30
$3.89
Portata 52W:
$1.53
$4.05
Inventiva Adr Stock (IVA) Company Profile
Confronta IVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.3819 | 372.13M | 16.82M | -112.19M | -91.84M | -2.2183 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-21 | Iniziato | TD Cowen | Buy |
| 2024-11-12 | Iniziato | UBS | Neutral |
| 2023-10-27 | Iniziato | Canaccord Genuity | Buy |
| 2023-05-31 | Iniziato | ROTH MKM | Buy |
| 2023-05-19 | Aggiornamento | Societe Generale | Sell → Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2022-11-15 | Downgrade | Societe Generale | Buy → Sell |
| 2021-03-08 | Downgrade | Societe Generale | Buy → Sell |
| 2020-08-05 | Iniziato | ROTH Capital | Buy |
| 2020-08-04 | Iniziato | Guggenheim | Buy |
| 2020-08-04 | Iniziato | Stifel | Buy |
Mostra tutto
Inventiva Adr Borsa (IVA) Ultime notizie
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright - TipRanks
Stifel maintains Buy on Inventiva shares with $17 target - Investing.com
Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée - GlobeNewswire Inc.
Inventiva SA ADR Reports 2024 Financial Results and Strategic Updates - TipRanks
Inventiva earnings missed by $0.03, revenue topped estimates - Investing.com
Top 10 Best Indian Companies In Smart Grids Solutions 2025 - Inventiva
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - inventiva.co.in
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Nasdaq
NOTA, No Votes and Unopposed Nominations: The Grey Areas of the Indian Election Process Explained - inventiva.co.in
symbol__ Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
Top 10 Best Handicraft Companies In USA 2023 - inventiva.co.in
Top 20 Best Hardware & Networking Company In India 2023 - Inventiva
Inventiva SaAdr Share Price Today (NASDAQ: IVA)Inventiva SaAdr Stock Price Live Quote - INDmoney
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Inventiva Adr Azioni (IVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):